Emerging Clinical Trials In Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
{{Infobox
|title=Emerging Clinical Trials in Neurodegeneration
|category=Treatment
|target=Alzheimer's Disease, Parkinson's Disease, ALS, Huntington's Disease
|status=Investigational
|phase=Phase I-III
}}
- NCT04770296
- Long-term safety and efficacy
- Results: Continued benefit over 3 years
- NCT05026866
- Primary prevention trial
- Cognitively normal with amyloid
- Phase II: Positive signal in mild AD
- Novel anti-amyloid antibody
- Phase II: Tau antibody
- Targeting extracellular tau
- Anti-tau antibody
- Molecule smaller than antibodies
- Anti-TREM2 antibody
- Enhances microglial function
- Phase II: INVOKE-2 trial
- Tau vaccine
- Phase II: Positive immune response
- Gene therapy delivering GDNF
- Phase I/II: Intraputaminal delivery
- NCT02881444
- LRRK2 inhibitor
- Phase II: LUMA and LIGHTTRIAL
- Target: G2019S and idiopathic PD
- Anti-alpha-synuclein antibody
- Phase II: PASADENA trial
- Did not meet primary endpoint
- Anti-alpha-synuclein antibody
- Phase II: SPARK
- Did not meet primary endpoint
- Gene therapy for AADC deficiency
- Phase I/II: PD with motor fluctuations
- NCT03075644
- ASO for SOD1 mutations
- VALOR trial: Positive in fast progressors
- FDA approved for SOD1-ALS
- ASO for FUS mutations
- Phase I/II: FUS-ALS
- 70% reduction in FUS protein
- ASO targeting C9orf72 repeat
- Phase I/II: FOCUS-C9
- Targeting both sense and antisense
- ASO for C9orf72
- Phase I: Completed
- Gold nanocrystals
- Phase II: REPAIR-AD, REPAIR-PD
- Energy metabolism enhancement
- Sodium phenylbutyrate + taurursodiol
- Phase III: CENTAUR
- FDA approved for ALS
- Fast skeletal muscle troponin activator
- Phase II: FORTITUDE-ALS
- Muscle strength preservation
- ASO targeting HTT
- GENERATION-HD1: Trial stopped
- Future trials with lower dose
- Small molecule
- Phase I/II: Ongoing
- Sigma-1 receptor agonist
- Phase II: PRIDE-HD
- Motor function improvement
- GABA-A modulator
- Phase II: Motor function
- Progranulin enhancer
- Phase II: INFRONT-3
- Progranulin deficiency
- Ionis/Biogen program
- Preclinical
- Tau antibody
- Phase II: LIFT-TD
- FTD due to tau
- Flortaucipir (AV-1451)
- Approved for AD
- Research in other diseases
- RT-QuIC, PMCA
- Diagnostic accuracy studies
- Clinical trial enrichment
- Biomarker-positive populations
- Genetic subtypes
- Stage-specific populations
- Digital biomarkers
- Composite endpoints
- Patient-reported outcomes
- Platform trials
- Sample size re-estimation
- Interim analyses
The study of Emerging Clinical Trials In Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Cummings J, et al. Alzheimers Dement. 2024;20(1):285-307. PMID:38251820
[2] Karch CM, et al. Nat Rev Neurol. 2024;20(1):3-14. PMID:38148393
[3] Pagano G, et al. Nat Rev Neurol. 2024;20(5):267-279. PMID:38538816
[4] Benatar M, et al. Nat Rev Neurol. 2023;19(11):645-656. PMID:37951931
[5] Tabrizi SJ, et al. Nat Rev Neurol. 2023;19(12):717-730. PMID:37993564
[6] Rascovsky K, et al. Brain. 2024;147(1):1-16. PMID:38150092
[7] Miller RG, et al. Nat Rev Neurol. 2024;20(2):73-84. PMID:38212345
[8] Aarsland D, et al. Nat Rev Dis Primers. 2024;10(1):1-24. PMID:38558891